Posted by Michael Wonder on 31 Mar 2025
IDEAYA Biosciences receives US FDA breakthrough therapy designation for darovasertib monotherapy in neo-adjuvant uveal melanoma
31 March 2025 - Breakthrough therapy application was supported by updated clinical data from Phase 2 neo-adjuvant uveal melanoma trial that we are targeting to present at medical conferences in mid-2025 and H2 2025.
IDEAYA Biosciences today announced that the US FDA has granted breakthrough therapy designation for darovasertib, a potential first in class protein kinase C inhibitor, for the neo-adjuvant treatment of adult patients with primary uveal melanoma for whom enucleation has been recommended.
